Abstract:BACKGROUND:Gout is the most common inflammatory arthritis, which, if left untreated or inadequately treated, will lead to joint destruction, bone erosion and disability due to the crystal deposition. Uric acid transporter 1 (URAT1) was the promising therapeutic target for urate-lowering therapy.OBJECTIVE:The goal of this work is to understand the structure-activity relationship (SAR) of a potent lesinurad-based hit, sodium 2-((5-bromo-4-((4-cyclopropyl-naphth-1-yl)methyl)-4H-1,2,4-triazol-3- yl)thio)acetate (1c), and based on that discover a more potent URAT1 inhibitor.METHODS:The SAR of 1c was systematically explored and the in vitro URAT1 inhibitory activity of synthesized compounds 1a-1t was determined by the inhibition of URAT1-mediated [8-14C]uric acid uptake by human embryonic kidney 293 (HEK293) cells stably expressing human URAT1.RESULTS:Twenty compounds 1a-1t were synthesized. SAR analysis was performed. Two highly active URAT1 inhibitors, sodium 2-((5-bromo-4-((4-n-propylnaphth-1-yl)methyl)-4H-1,2,4-triazol-3- yl)thio)acetate (1j) and sodium 2-((5-bromo-4-((4-bromonaphth-1-yl)methyl)-4H-1,2,4-triazol-3- yl)thio)acetate (1m), were identified, which were 78- and 76-fold more active than parent lesinurad in in vitro URAT1 inhibitory assay, respectively (IC50 values for 1j and 1m were 0.092 μM and 0.094 μM, respectively, against human URAT1 vs 7.18 μM for lesinurad).CONCLUSION:Two highly active URAT1 inhibitors were discovered. The SAR exploration also identified more flexible naphthyltriazolylmethane as a novel molecular skeleton that will be valuable for the design of URAT1 inhibitors, as indicated by the observation that many of the synthesized naphthyltriazolylmethane- bearing derivatives (1b-1d, 1g, 1j and 1m) showed significantly improved UART1 inhibitory activity (sub-micromolar IC50 values) as compared with lesinurad which has the rigid naphthyltriazole skeleton.

Discovery of a Novel Thienopyrimidine Compound as a Urate Transporter 1 and Glucose Transporter 9 Dual Inhibitor with Improved Efficacy and Favorable Druggability

Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability

Design, Synthesis and Activity Evaluation of Novel Lesinurad Analogues Containing Thienopyrimidinone or Pyridine Substructure As Human Urate Transporter 1 Inhibitors.

Novel Human Urate Transporter 1 Inhibitors As Hypouricemic Drug Candidates With Favorable Druggability

Discovery of a Potent and Orally Bioavailable Xanthine Oxidase/Urate Transporter 1 Dual Inhibitor as a Potential Treatment for Hyperuricemia and Gout

Discovery of Flexible Naphthyltriazolylmethane-based Thioacetic Acids As Highly Active Uric Acid Transporter 1 (URAT1) Inhibitors for the Treatment of Hyperuricemia of Gout

Discovery Of A Flexible Triazolylbutanoic Acid As A Highly Potent Uric Acid Transporter 1 (Urat1) Inhibitor

Discovery and Optimization of Thienopyridine Derivatives As Novel Urea Transporter Inhibitors.

Design, Synthesis and Biological Activity of Low-Molecular-Weight URAT1 Inhibitors

Proline-derived quinoline formamide compounds as human urate transporter 1 inhibitors with potent uric acid-lowering activities

Discovery of Novel Curcumin Derivatives Targeting Xanthine Oxidase and Urate Transporter 1 As Anti-Hyperuricemic Agents

Molecular basis of the urate transporter URAT1 inhibition by gout drugs

Discovery of novel benzbromarone analogs with improved pharmacokinetics and benign toxicity profiles as antihyperuricemic agents

Design, Synthesis and Biological Activity Evaluation of Novel URAT1 Inhibitors

Transport mechanism and structural pharmacology of human urate transporter URAT1

Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020-present)

A System for Discovering Novel Uricosurics Targeting Urate Transporter 1 Based on In Vitro and In Vivo Modeling

Discovery of novel 1,2,4-triazole derivatives as xanthine oxidoreductase inhibitors with hypouricemic effects

Design, synthesis, and biological evaluation of 3-phenyl substituted pyridine derivatives as potential dual inhibitors of XOR and URAT1

Identification of N-phenyl-N-(quinolin-4-yl) Amino Carboxylic Acids As URAT1 Inhibitors with Hypouricemic Effects

Lesinurad, a Novel, Oral Compound for Gout, Acts to Decrease Serum Uric Acid Through Inhibition of Urate Transporters in the Kidney